External publications

Responses to the Third Lancet Commission on Investing in Health from Denmark, Germany, and Norway

Alfvén, Tobias / Angela Y. Chang / Hanna Ohm Cleaver / Anna-Katharina Hornidge / Steven L. B. Jensen / Eirik Mofoss / Fride Nordstrand Nilsen / Ole F. Norheim / Marco Schäferhoff / Martin Siegel / Christoph Strupat
External Publications (2025)

in: The Lancet Regional Health – Europe 56, article 101377

DOI: https://doi.org/10.1016/j.lanepe.2025.101377
Open Access

The case for global health today remains powerful, compelling and now also more urgent than ever. The third report by the Lancet Commission on Investing in Health (CIH3) laid out starkly different scenarios: it emphasised the opportunity to halve premature mortality globally by 2050, but also warned of a 48% risk that a new pandemic costing 25 million lives or more will happen by 2050, and that cuts in development assistance for health (DAH) will jeopardise hard-earned gains. Since the release of the CIH3 report, the Trump administration in the USA has made substantial cuts to DAH, and the UK announced it would reduce aid spending from 0.5% of gross national income (GNI) to 0.3% of GNI in 2027. Expert groups from three European countries—Norway, Denmark, and Germany—have responded to CIH3 and published reports on how these countries should renew their engagement in global health. All three reports endorse the Commission's goal of halving premature mortality by 2050 (the 50-by-50 goal).